People newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) who have lower exercise capacity and poorer breathing efficiency during exercise tend to also report more severe anxiety and depressive symptoms, according to a new study in China. “The present findings … support greater attention to psychological symptoms during the…
News
Artificial intelligence (AI) tools using machine learning may help doctors predict how a pulmonary arterial hypertension (PAH) patient’s ability to walk might change over the next year, a study from Germany found. The researchers said more study is needed before the machine learning model, which uses clinical data available…
Note: This story was updated Sept. 30, 2026, to clarify that the Chiesi Group is no longer collaborating with Gossamer Bio in the development, regulatory activities, or commercialization of seralutinib. Gossamer Bio has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of seralutinib, an…
The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Winrevair (sotatercept-csrk), an approved injection therapy for adults with pulmonary arterial hypertension (PAH) marketed by Merck. The most notable change in this update is the addition of a contraindication (a…
A national database study found substantial variation in how clinicians manage people hospitalized with pulmonary arterial hypertension (PAH) who presented with shock, a life-threatening lack of blood flow to the body’s organs. Researchers identified 25 different initial treatment strategies involving vasoactive medications, drugs that adjust blood pressure and heart…
Measurements that look at the interplay between the pulmonary arteries and the heart may help predict the likelihood of survival among people with all forms of pulmonary hypertension (PH), according to a study. These measurements were able to predict mortality risk even in mild PH, whereas conventional disease severity…
Mosliciguat, an inhaled treatment being developed by Pulmovant, was well tolerated and more effective than a placebo at improving blood flow through the lungs of adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD), supporting its move into Phase 3 clinical testing, which is already underway. That’s…
The PAH Initiative will once again host a live broadcast event — this time focusing on how oxygen therapy can become part of the care plan for people living with pulmonary arterial hypertension (PAH) — and registration for the free hour-long program is now open. The event, called…
A noninvasive measure of heart and blood vessel function called the TAPSE/sPAP ratio can help doctors objectively assess the severity of day-to-day symptoms in people with pulmonary arterial hypertension (PAH), according to a new study. Researchers found that lower ratio values closely mirror greater physical limitations in patients, providing…
A measurement taken by heart MRI was linked to several invasive measures used to assess pulmonary hypertension (PH), a new study shows. The measurement, known as T2RV/LV, “represents a highly promising non-invasive biomarker for risk stratification, disease monitoring, and assessment of treatment response in PH,” the researchers wrote. They…
Two blood-based biomarkers — GDF-15 and NT-proBNP — most accurately distinguished adults with pulmonary hypertension (PH) from healthy individuals in a study that compared five biomarkers. The retrospective study, conducted at Beijing Anzhen Hospital in China, evaluated traditional and newer biomarkers across the four main clinical subtypes of…
Adults with pulmonary arterial hypertension (PAH) taking Remodulin (treprostinil) or Veletri (epoprostenol) safely switched to Uptravi (selexipag) during carefully monitored hospital stays using a rapid dose-titration plan, a new study reports. The findings may help guide clinicians who are transitioning appropriate PAH patients from infusion therapy…
